E-viri
Recenzirano
Odprti dostop
-
Dabisch, Paul A.; Biryukov, Jennifer; Beck, Katie; Boydston, Jeremy A.; Sanjak, Jaleal S.; Herzog, Artemas; Green, Brian; Williams, Gregory; Yeager, John; Bohannon, Jordan K.; Holland, Brian; Miller, David; Reese, Amy L.; Freeburger, Denise; Miller, Susan; Jenkins, Tammy; Rippeon, Sherry; Miller, James; Clarke, David; Manan, Emmanuel; Patty, Ashley; Rhodes, Kim; Sweeney, Tina; Winpigler, Michael; Price, Owen; Rodriguez, Jason; Altamura, Louis A.; Zimmerman, Heather; Hail, Alec S.; Wahl, Victoria; Hevey, Michael
PLoS pathogens, 08/2021, Letnik: 17, Številka: 8Journal Article
While evidence exists supporting the potential for aerosol transmission of SARS-CoV-2, the infectious dose by inhalation remains unknown. In the present study, the probability of infection following inhalation of SARS-CoV-2 was dose-dependent in a nonhuman primate model of inhalational COVID-19. The median infectious dose, assessed by seroconversion, was 52 TCID 50 (95% CI: 23–363 TCID 50 ), and was significantly lower than the median dose for fever (256 TCID 50 , 95% CI: 102–603 TCID 50 ), resulting in a group of animals that developed an immune response post-exposure but did not develop fever or other clinical signs of infection. In a subset of these animals, virus was detected in nasopharyngeal and/or oropharyngeal swabs, suggesting that infected animals without signs of disease are able to shed virus and may be infectious, which is consistent with reports of asymptomatic spread in human cases of COVID-19. These results suggest that differences in exposure dose may be a factor influencing disease presentation in humans, and reinforce the importance of public health measures that limit exposure dose, such as social distancing, masking, and increased ventilation. The dose-response data provided by this study are important to inform disease transmission and hazard modeling, and, ultimately, mitigation strategies. Additionally, these data will be useful to inform dose selection in future studies examining the efficacy of therapeutics and vaccines against inhalational COVID-19, and as a baseline in healthy, young adult animals for assessment of the importance of other factors, such as age, comorbidities, and viral variant, on the infectious dose and disease presentation.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.